Berg, AZ to discover neurological treatments using AI

Berg LLC (Framingham, Mass.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to discover targets and therapeutics to treat neurological disorders, including Parkinson's disease.

The pharma will provide Berg with its CNS fragment library, which the biotech will use with its interrogative biology platform to identify drug candidates. Berg's Chief Precision Medicine Officer Michael Kiebish told BioCentury that AZ's library comprises fragments of existing drugs which Berg will use against its undisclosed PD target. Kiebish declined to disclose financial terms...